Altamira Therapeutics Ltd. – NASDAQ:EARS

Add to watchlist

$3.045

+2.60

+596%

Market open

Closed in 3 minutes

-85.62%

month

-85.62%

quarter

-85.05%

year

Market Cap	4.21M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-228.57

Revenue	N/A
EBITDA	2.02M
Income	-15.83M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Altamira Therapeutics Ltd. (NASDAQ:EARS): Profit margin
Sep 2022	-458.69K	-9.61M	2095.32%
Dec 2022	0	-802.07K
Mar 2023	52.73K	-2.71M	-5139.89%
Jun 2023	52.73K	-2.71M	-5139.89%

Altamira Therapeutics Ltd. (NASDAQ:EARS): Debt to assets
Mar 2023	6203962	8.02M	129.41%
Jun 2023	6203962	8.02M	129.41%
Sep 2023	7694259	888.91K	11.55%
Dec 2023	7694259	1.23M	16.06%

Altamira Therapeutics Ltd. (NASDAQ:EARS): Cash Flow
Sep 2022	-1.54M	-304.13K	1.64M
Dec 2022	-1.54M	-304.13K	1.64M
Mar 2023	-3.85M	120	3.84M
Jun 2023	-3.85M	120	3.84M

Altamira Therapeutics Ltd. alternative data

Altamira Therapeutics Ltd.
Employees

Altamira Therapeutics Ltd. (NASDAQ:EARS): Employee count
Aug 2023	8
Sep 2023	8
Oct 2023	8
Nov 2023	8
Dec 2023	8
Jan 2024	8
Feb 2024	8
Mar 2024	8
Apr 2024	8
May 2024	8
Jun 2024	8
Jul 2024	8

Altamira Therapeutics Ltd.
Earnings Call Transcripts

Quarter	Transcript
Q2 2020 17 Sep 2020	Q2 2020 Earnings Call Transcript
Q2 2019 15 Aug 2019	Q2 2019 Earnings Call Transcript
Q4 2018 14 Mar 2019	Q4 2018 Earnings Call Transcript
Q3 2018 15 Nov 2018	Q3 2018 Earnings Call Transcript

EARS earnings call transcripts

Altamira Therapeutics Ltd.
Executives

Insider	Age	Since	Compensation
Dr. Thomas Meyer (1968) Founder, Chairman, Chief Executive Officer & MD	57		$458,310
Mr. Elmar Schaerli CPA Chief Financial Officer

Frequently Asked Questions (FAQ)

What's the price of Altamira Therapeutics Ltd. stock today?

One share of Altamira Therapeutics Ltd. stock can currently be purchased for approximately $3.05.
When is Altamira Therapeutics Ltd.'s next earnings date?

Unfortunately, Altamira Therapeutics Ltd.'s (EARS) next earnings date is currently unknown.
Does Altamira Therapeutics Ltd. pay dividends?

No, Altamira Therapeutics Ltd. does not pay dividends.
How much money does Altamira Therapeutics Ltd. make?

Altamira Therapeutics Ltd. has a market capitalization of 4.21M.
What is Altamira Therapeutics Ltd.'s stock symbol?

Altamira Therapeutics Ltd. is traded on the NASDAQ under the ticker symbol "EARS".
What is Altamira Therapeutics Ltd.'s primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Altamira Therapeutics Ltd.?

Shares of Altamira Therapeutics Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Altamira Therapeutics Ltd.'s key executives?
Altamira Therapeutics Ltd.'s management team includes the following people:
- Dr. Thomas Meyer Founder, Chairman, Chief Executive Officer & MD(age: 57, pay: $458,310)
- Mr. Elmar Schaerli CPA Chief Financial Officer
Is Altamira Therapeutics Ltd. founder-led company?

Yes, Altamira Therapeutics Ltd. is a company led by its founder Dr. Thomas Meyer.
How many employees does Altamira Therapeutics Ltd. have?

As Jul 2024, Altamira Therapeutics Ltd. employs 8 workers.
When Altamira Therapeutics Ltd. went public?

Altamira Therapeutics Ltd. is publicly traded company for more then 11 years since IPO on 6 Aug 2014.
What is Altamira Therapeutics Ltd.'s official website?

The official website for Altamira Therapeutics Ltd. is aurismedical.com.
Where are Altamira Therapeutics Ltd.'s headquarters?

Altamira Therapeutics Ltd. is headquartered at Bahnhofstrasse 21, Zug, ZUG.
How can i contact Altamira Therapeutics Ltd.?

Altamira Therapeutics Ltd.'s mailing address is Bahnhofstrasse 21, Zug, ZUG and company can be reached via phone at +41 61 201 13 50.

Altamira Therapeutics Ltd.

aurismedical.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The company is headquartered in Zug, Zug and currently employs 11 full-time employees. The firm focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The firm operates through subsidiaries in Switzerland, Ireland and the United States.

+41 61 201 13 50

Bahnhofstrasse 21
Zug, ZUG HM 11

CIK: 0001601936
ISIN: BMG070252017
CUSIP: G07025201